Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen, SynX, Friedrich Miescher Institute for Biomedical Research, US Food and Drug Administration, US Department of Energy s Joint Genome Institute, Rosetta Biosoftware


Nanogen Subsidiary SynX Signs on Five European Distributors

Nanogen’s subsidiary SynX has signed on five European distributors for its point-of-care diagnostics products, Nanogen said this week.

The new distributors, which Nanogen did not name, expand SynX’s coverage to 28 European countries.

They will distribute and market SynX’s point-of-care tests and research products for congestive heart failure and myocardial infarction.

SynX said its CHF diagnostic test is expected to launch this year.

FMI Licenses Genedata’s Expressionist Software

The Friedrich Miescher Institute for Biomedical Research, a branch of Novartis Research Foundation based in Basel, Switzerland, has licensed Genedata’s Expressionist computational system for gene expression analysis for use in its research, Genedata and FMI jointly announced last week.

Expressionist is a bioinformatics tool that integrates proteomics and transcriptomics data into a single environment. FMI said that it will use the system for its research in epigenetics, growth control, and neurobiology.

Financial details of the agreement were not provided.

PGx Voluntary Submissions Guidance to be Made Available Within a Week

The US Food and Drug Administration's guideline for voluntarily submitting pharmacogenomics data will be available on a special FDA web site within a week, an FDA official said during a lecture at the Society of Toxicology meeting held in New Orleans this week.

Pharmacogenomics Reporter, a sister publication of BioArray News, reported that Federico Goodsaid, an official at the agency's Office of Clinical Pharmacology and Biopharmaceutics, said that the full Pharmacogenomic Data Submissions guidance will be formally released sometime this month.

The FDA currently favors the use of expert advisory committees or public scientific organizations to decide which biomarkers qualify as known, valid biomarkers, said Goodsaid.

The document is designed to encourage drug makers to use pharmacogenomics technologies in their drug-discovery efforts and submit some of their findings as a way to help the FDA broaden its knowledge of the technologies.

GI Launches Public Online Genome Data Clearinghouse

The US Department of Energy’s Joint Genome Institute released this week its Integrated Microbial Genomes data-management system, JGI said.

IMG is a state-funded offering to the global research community that can be used as a clearinghouse for datasets produced by JGI and other DNA-sequencing centers.

According to JGI, the IMG system currently features over 200 organisms, with an additional 200 already in the queue for 2005. The institute is offering the system to the public on its website. and is planning a series of presentations at various locations throughout March and April to acquaint the research community with IMG.

UK’s CSC/Imperial College Microarray Center to Use Rosetta Resolver

Rosetta Biosoftware said this week that the MRC Clinical Sciences Center and Imperial College London have jointly licensed the Rosetta Resolver gene expression analysis platform for use in the CSC/Imperial College Microarray Center.

The British research institutes licensed the system with funding from the UK’s Medical Research Council and the British Heart Foundation.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.